1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,476 | 1,582 | 02.10. | |
| 1,496 | 1,562 | 02.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten
Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.09. | SynAct Pharma to Participate in Investor and Partnering Conferences | 307 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 22, 2026 / SynAct Pharma AB (publ) ("SynAct") (STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic... ► Artikel lesen | |
| 16.09. | SynAct Pharma: WHO Identifies Resomelagon as One Of Six Dengue Drug Candidates with Evidence Supporting Further Clinical Development | 365 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 16, 2026 / SynAct Pharma AB (publ) ("SynAct") (STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic... ► Artikel lesen | |
| 16.09. | SynAct Pharma AB: WHO identifies resomelagon as one of six dengue drug candidates with evidence supporting further clinical development | 344 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as "pro-resolution"... ► Artikel lesen | |
| SYNACT PHARMA Aktie jetzt für 0€ handeln | |||||
| 07.09. | SynAct Pharma: Further Analysis of the Phase 2b ADVANCE Study Reinforces Phase 2b EXPAND Results and Supports Phase 3 Development - FDA Discussions on Trial Design Planned for Q4 2026 | 498 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 7, 2026 / SynAct Pharma AB (publ) ("SynAct")(STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach... ► Artikel lesen | |
| 03.09. | SynAct Pharma's CEO and CSO Sell Shares | 263 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 3, 2026 / SynAct Pharma AB (STO:SYNACT) ("SynAct Pharma" or the "Company") today announces that the Company's Chief Executive Officer, Jeppe Øvlesen, and the Company's... ► Artikel lesen | |
| 20.08. | SynAct Pharma AB: SynAct Pharma publishes Q2 2026 interim results | 218 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the second quarter 2026.
"With new capital secured and active partnering discussions underway, we are positionedto pursue the... ► Artikel lesen | |
| 19.08. | SynAct Pharma AB: SynAct Pharma progresses first commercial agreement on resomelagon for treatment of dengue in Brazil - term sheet signed | 244 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the company has signed... ► Artikel lesen | |
| 05.08. | SynAct Pharma AB: SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation | 587 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has issued a favorable Decision on Appeal in... ► Artikel lesen | |
| 20.07. | SynAct Pharma AB: SynAct Pharma strengthens financial position and strategic flexibility to advance partnering discussions and Phase III readiness | 829 | GlobeNewswire (Europe) | SynAct Pharma AB ("SynAct" or the "Company") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company developing resolution therapies for inflammatory diseases, today announced that it has... ► Artikel lesen | |
| 29.06. | SynAct Pharma AB: BIO International USA confirms growing interest in resomelagon and SynAct Pharma following the positive effects of the ADVANCE study | 833 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on treating inflammation through resolution therapy, today provides an update following... ► Artikel lesen | |
| 15.06. | SynAct Pharma AB: Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis - supports phase 3 design, regulatory interactions, and partnering | 521 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, reported today that resomelagon in combination... ► Artikel lesen | |
| 12.06. | SynAct Pharma AB: SynAct obtains key US patent for resomelagon securing exclusivity until 2044 | 654 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") announced today that the United States Patent and Trademark Office (USPTO) have provided the issue notification of US patent 12,661,336 with issue date 23 June 2026... ► Artikel lesen | |
| 11.06. | SynAct Pharma AB: Report from the 2026 Annual General Meeting of SynAct Pharma AB (publ) | 480 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) held its Annual General Meeting today, Thursday 11 June 2026, at the offices of MAQS Advokatbyrå in Stockholm. Attorney Eric Ehrencrona from MAQS Advokatbyrå was elected as chairman... ► Artikel lesen | |
| 27.05. | SynAct Pharma AB: SynAct Pharma publishes Q1 2026 interim results | 391 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the first quarter 2026.
"As we close the first quarter of 2026, SynAct Pharma is in a stronger position than at any previous... ► Artikel lesen | |
| 06.05. | SynAct Pharma AB: SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study | 658 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has successfully completed dosing... ► Artikel lesen | |
| 26.03. | SynAct Pharma AB: SynAct Pharma doses first patients in the Phase 2 RESOVIR-2 study with resomelagon | 305 | GlobeNewswire (Europe) | SynAct Pharma AB ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the first patients were dosed... ► Artikel lesen | |
| 03.03. | SynAct Pharma - Multiple shots on goal in 2026 for resomelagon | 623 | Edison Investment Research | SynAct Pharma's FY25 results reflect a year of solid execution, highlighted by the continued advancement of lead asset resomelagon in the Phase IIb ADVANCE trial in rheumatoid arthritis (RA). With enrolment... ► Artikel lesen | |
| 24.02. | SynAct Pharma AB: SynAct Pharma appoints Ann Kristin Led as Chief Financial Officer | 283 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced the appointment of Ann Kristin... ► Artikel lesen | |
| 18.02. | SynAct Pharma AB: SynAct Pharma Year-end Report 2025 | 348 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today announced its Year-end Report 2025
"As we close the fourth quarter and conclude 2025, I am pleased with the steady progress SynAct Pharma has made across clinical... ► Artikel lesen | |
| 10.02. | SynAct Pharma - Resomelagon progresses in RA, viral infections | 635 | Edison Investment Research | SynAct Pharma has completed patient recruitment for its Phase IIb ADVANCE trial (n=240) in rheumatoid arthritis (RA), while initiating the Phase II RESPIRE study in hospitalised with respiratory insufficiency... ► Artikel lesen |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 44,940 | -1,01 % | 90 Milliarden US-Dollar bis 2030: Wie Bayer, Mesoblast und NurExone regenerative Medizin unterschiedlich entwickeln | ||
| ABBVIE | 231,00 | -0,35 % | AbbVie To Present New Dermatology Data At 2026 EADV Congress | WASHINGTON (dpa-AFX) - AbbVie (ABBV) said it will present new clinical and real-world data across its dermatology portfolio at the 2026 European Academy of Dermatology and Venereology (EADV)... ► Artikel lesen | |
| ELI LILLY | 1.019,20 | +0,33 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| MERCK & CO | 128,18 | 0,00 % | AstraZeneca-Summit, Novo-Hengrui, Merck-Fierce Pharma Asia | ||
| BRISTOL-MYERS SQUIBB | 54,11 | -0,39 % | Dividendenbekanntmachungen (02.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACME UNITED CORPORATION US0048161048 0,16 USD 0,1423 EUR ALICO INC US0162301040 0,05 USD 0,0444 EUR ATN INTERNATIONAL INC US00215F1075 0... ► Artikel lesen | |
| INNOCAN PHARMA | 1,265 | -0,78 % | Innocan Pharma Corporation: VALITIC Expands Retail Industry Visibility Through Shoptalk Fall 2026 in Nashville, USA | HERZLIYA, Israel and CALGARY, Alberta, Sept. 29, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (OTCQB: INNPF) ("Innocan" or the "Company"), through B.I. Sky Global Ltd., its consumer... ► Artikel lesen | |
| DOCMORRIS | 13,840 | -0,36 % | Aktien Europa: Moderate Gewinne - Ölpreise etwas gesunken | PARIS/LONDON/ZÜRICH (dpa-AFX) - Europas Aktienmärkte haben sich am Dienstag nach verhaltenem Start robust gezeigt. Nach Ansicht von Marktanalyst Andreas Lipkow vom Broker CMC Markets bleiben die Anleger... ► Artikel lesen | |
| INCYTE | 102,25 | -0,20 % | Mirum Pharmaceuticals, Inc. and Incyte: Mirum Pharmaceuticals und Incyte melden FDA-Zulassung für Atebrioz (Zilurgisertib) für erwachsene und pädiatrische Patienten mit Fibrodysplasia ossificans progressiva | - Einmal täglich oral verabreichter ALK2-Hemmer erhält Zulassung zur Reduzierung des Volumens der gesamten neuen heterotopischen Verknöcherung bei Patienten mit FOP im Alter von über 12 Jahren ... ► Artikel lesen | |
| SINOPHARM | 1,649 | 0,00 % | Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 0,900 | 0,00 % | Happy Belly Food Group Inc.: Happy Belly Food Group Announces Grand Opening of First U.S. Heal Wellness Location in Lubbock, Texas | Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands... ► Artikel lesen | |
| COMPASS PATHWAYS | 10,600 | 0,00 % | Compass Pathfinder Limited: Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards... ► Artikel lesen | |
| HIGH TIDE | 2,305 | -1,28 % | High Tide zum sechsten Mal in Folge in die "Report on Business"-Rangliste der wachstumsstärksten Unternehmen Kanadas aufgenommen | CALGARY, AB, 28. September 2026 / IRW-Press / High Tide Inc. ("High Tide" oder das "Unternehmen") (Nasdaq: HITI) (TSXV: HITI) (FWB: 2LYA), ein erfolgreiches und
auf den Einzelhandel ausgerichtetes... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 268,00 | -0,74 % | Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones | ||
| JAZZ PHARMACEUTICALS | 210,60 | +0,62 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences | Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy
Transaction strengthens Jazz's epilepsy pipeline... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 10,400 | -0,48 % | SONDERMELDUNG: Könnte die Aktie von SELLAS Life Sciences Group Inc jetzt komplett einbrechen? - Jetzt handeln, noch vor dem Wochenende! |
Das Unternehmen SYNACT PHARMA AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,032 (+2,15 %) liegt der Kurs bei 1,520 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNACT PHARMA AB finden Sie auf Wallstreet Online.